Segments of Business and Geographic Areas (Tables)

9 Months Ended

Oct. 02, 2016

Segment Reporting [Abstract]

Sales By Segment Of Business

	Fiscal Third Quarters Ended
(Dollars in Millions)	October 2, 2016		September 27, 2015	Percent Change
Consumer
United States	$	1,291	1,277	1.1	%
International	1,970		2,037	(3.3	)
Total	3,261		3,314	(1.6	)
Pharmaceutical
United States	5,042		4,509	11.8
International	3,358		3,185	5.4
Total	8,400		7,694	9.2
Medical Devices
United States	3,048		3,005	1.4
International	3,111		3,089	0.7
Total	6,159		6,094	1.1
Worldwide
United States	9,381		8,791	6.7
International	8,439		8,311	1.5
Total	$	17,820	17,102	4.2	%

	Fiscal Nine Months Ended
(Dollars in Millions)	October 2, 2016		September 27, 2015	Percent Change
Consumer
United States	$	4,033	3,991	1.1	%
International	5,842		6,196	(5.7	)
Total	9,875		10,187	(3.1	)
Pharmaceutical
United States	15,123		13,423	12.7
International	10,109		9,943	1.7
Total	25,232		23,366	8.0
Medical Devices
United States	9,118		8,980	1.5
International	9,559		9,730	(1.8	)
Total	18,677		18,710	(0.2	)
Worldwide
United States	28,274		26,394	7.1
International	25,510		25,869	(1.4	)
Total	$	53,784	52,263	2.9	%

Operating Profit by Segment of Business

	Fiscal Third Quarters Ended
(Dollars in Millions)	October 2, 2016		September 27, 2015	Percent Change
Consumer(1)	$	679	811	(16.3	)%
Pharmaceutical(2)	3,309		2,732	21.1
Medical Devices(3)	1,526		835	82.8
Segments operating profit	5,514		4,378	25.9
Less: Expense not allocated to segments (4)	233		256
Worldwide income before tax	$	5,281	4,122	28.1	%

	Fiscal Nine Months Ended
(Dollars in Millions)	October 2, 2016		September 27, 2015	Percent Change
Consumer(1)	$	1,816	1,772	2.5	%
Pharmaceutical(2)	10,340		9,816	5.3
Medical Devices(3)	4,041		4,640	(12.9	)
Segments operating profit	16,197		16,228	(0.2	)
Less: Expense not allocated to segments (4)	718		790
Worldwide income before taxes	$	15,479	15,438	0.3	%

(1) Includes a gain of $229 million from the divestiture of the SPLENDA^® brand recorded in the fiscal third quarter and fiscal nine months of 2015.

(2) Includes litigation expense of $136 million recorded in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA^® (tapentadol), NUCYNTA^® ER (tapentadol extended-release tablets), and NUCYNTA^® (tapentadol) oral solution. Includes a positive adjustment of $513 million and $462 million to previous reserve estimates in the fiscal nine months of 2016 and 2015, respectively.

(3) Includes a restructuring related charge of $109 million and $387 million in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $55 million and $731 million recorded in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $409 million in the fiscal third quarter of 2015. Includes a $346 million intangible asset write-down related to Acclarent recorded in the fiscal third quarter and fiscal nine months of 2015. The fiscal nine months of 2015 included $148 million for costs associated with the DePuy ASR^TM Hip program.

(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

	Fiscal Third Quarters Ended
(Dollars in Millions)	October 2, 2016		September 27, 2015	Percent Change
United States	$	9,381	8,791	6.7	%
Europe	3,832		3,802	0.8
Western Hemisphere, excluding U.S.	1,396		1,463	(4.6	)
Asia-Pacific, Africa	3,211		3,046	5.4
Total	$	17,820	17,102	4.2	%

	Fiscal Nine Months Ended
(Dollars in Millions)	October 2, 2016		September 27, 2015	Percent Change
United States	$	28,274	26,394	7.1	%
Europe	11,769		11,993	(1.9	)
Western Hemisphere, excluding U.S.	4,269		4,603	(7.3	)
Asia-Pacific, Africa	9,472		9,273	2.1
Total	$	53,784	52,263	2.9	%